PRVB - プロベンション・バイオ (Provention Bio Inc.)

PRVBのニュース

   Provention Bio to Present at the Stifel Virtual Healthcare Conference  2020/11/11 12:30:00 PR Newswire
RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18,…
   Oppenheimer Sees These 3 Stocks Skyrocketing Over 100%  2020/11/10 17:42:56 Yahoo Finance
The U.S. presidential election has come to a close, and Wall Street isn’t opposed to the administration change. Last week saw the S&P 500 notch its second-best performance during an election week on record, even as Trump’s chances of getting re-elected became slimer and slimer.Weighing in for Oppenheimer, Chief Investment Strategist John Stoltzfus noted, “What appears clear so far is that the equity markets are not averse to a change of administration stateside at least so long as the Republicans maintain control over the Senate. Checks and balances ‘on the Hill’ have been known to be important to investors over the course of history. The present in our view is no exception.”There is, however, some uncertainty surrounding the Senate, with the two runoff elections for seats in Georgia scheduled for January 5, only 15 days before Inauguration Day. That said, Stoltzfus points out that continued better-than-expected Q3 results from S&P 500-listed companies, economic data tied to job gains and a sharp decline in the unemployment rate have also been helping to prop stocks up.Taking Stoltzfus’ outlook into consideration, we wanted to take a closer look at three stocks earning a round of applause from Oppenheimer, with the firm’s analysts forecasting over 100% upside potential for each.
   Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/05 12:00:00 PR Newswire
RED BANK, N.J., Nov. 5, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported financial results for the third quarter ended September 30, 2020, and provided a business update. "We…
   Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals  2020/11/02 12:30:00 PR Newswire
RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and…
   Celiac Disease Foundation Partners with Provention Bio on Its Phase 2b Study of Celiac Disease Therapeutic PRV-015  2020/10/07 12:03:00 PR Newswire
LOS ANGELES, Oct. 7, 2020 /PRNewswire/ -- Building on its role as the nation's leading celiac disease patient advocacy organization and the largest nonprofit patient recruiter for celiac disease clinical trials and studies, the Celiac Disease Foundation is pleased to announce its…
   Provention Bio to Present at Upcoming Virtual Investor Conferences  2020/09/08 11:30:00 PR Newswire
RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at three upcoming virtual investor conferences in September: The…
   Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/06 11:00:00 PR Newswire
OLDWICK, N.J., Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2020 and provided a business…
   In-house counsel on the move: Rite Aid taps new GC as pharma, tech players shuffle top lawyers  2020/08/05 22:41:26 Reuters
Three companies with relatively pandemic-proof businesses - pharmacy and drugstore Rite Aid, online textbook rental company Chegg Inc and pharmaceutical company Provention Bio Inc - tapped new top lawyers this week.
   Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020  2020/07/30 11:00:00 PR Newswire
OLDWICK, N.J., July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursday, August…
   Why This Under-the-Radar Biotech Stock Could Skyrocket  2020/07/02 13:15:00 The Motley Fool
Provention Bio is developing a drug that could delay the onset of diabetes, and if it's successful, the company's stock could soar.
   Provention Bio (PRVB) Soars: Stock Adds 6.4% in Session  2020/04/01 13:09:00 Zacks Investment Research
Provention Bio (PRVB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
   Provention Bio to Present at Upcoming Conferences  2020/02/19 12:00:00 PR Newswire
OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming conferences: The 9th Annual SVB…
   Provention Bio Appoints Jason Hoitt as Chief Commercial Officer  2020/01/08 12:00:00 PR Newswire
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated…
   Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA  2019/12/12 12:00:00 PR Newswire
OLDWICK, N.J., Dec. 12, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B multidisciplinary meeting with the U.S. Food and Drug…
   Provention Bio Reports Third Quarter 2019 Financial Results  2019/11/05 21:05:00 PR Newswire
OLDWICK, N.J., Nov. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2019. "The PRV-031…

calendar